IKZF1 and pelvic inflammatory disease: Finally, we believe that this study defines AIOLOS HI as a clinical entity with incomplete clinical penetrance, expanding the spectrum of AIOLOS-associated diseases in patients with PID/IEI, as well as redefining the mechanistic structure and functions of AIOLOS, a major contributor to immune development and a key member of the IKAROS family of transcription factors.